US 2025/0051350 A1Published application

Dihydroartemisinin derivatives and the treatment of fibrotic diseases

AssigneeGreenStone Biosciences, Inc.

InventorsJoseph C. Wu, Honit Piplani, Hao Zhang, Rabindra Vishwadev Shivnaraine, Christopher David Yan

Life of this patent

Estimating the term…

Abstract

Compounds of formulae PT-1, PT-2, PT-4, PT-13, PT-14, PT-20, PT-23 to PT-25, and PT-27 to PT-30, and their salts, pharmaceutical formulations containing them, and the use of these derivatives for the treatment of fibrotic diseases.

Claims16

Dependent claims

A compound of any one of the formulae PT-1, PT-2, PT-4, PT-13, PT-14, PT-20, PT-23 to PT-25, and PT-27 to PT-30:

or a salt, especially a pharmaceutically acceptable salt, thereof.

Dependencies are inferred from the claim text.

Facts

Application: 18/777,326Filed 18 Jul 2024
Priority: 19 Jul 2023
Published: 13 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07D 493/18
In which the condensed system contains three hetero rings: bridged systems
A61K 31/357
Having oxygen as the only ring hetero atom, e.g. fungichromin: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/397
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having four-membered rings, e.g. azetidine
A61K 31/407
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: condensed with other…

Family

Application63/527,771Us provisional application · filed 19 Jul 2023
US 2025/0051350 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results